Duke University
The purpose of this study is to determine if the use of ReliZORB improves nutrition tolerance and helps critically ill patients meet their nutrition goals. Subjects in the intensive care unit will be enrolled and randomized 2:1 to receive ReliZORB or placebo cartridges with enteral feedings for 5 days. Blood and stool samples will be collected to test for nutrition and inflammation.
Multi Organ Failure
Critical Illness
Relizorb
Placebo
Phase 4
Study Type : | Interventional |
Estimated Enrollment : | 0 participants |
Masking: | Single |
Primary Purpose: | Treatment |
Official Title: | Single-center, Open-label, Prospective Randomized (Double-Blind) Study on the Use of ReliZORB™ for the Treatment of Feeding Intolerance in Critically Ill Adults With Multi Organ Failure |
Actual Study Start Date : | May 1, 2023 |
Estimated Primary Completion Date : | July 30, 2023 |
Estimated Study Completion Date : | January 30, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: ReliZORB ReliZORB enzyme cartridges will be used with enteral feedings for 5 days |
Drug: Relizorb |
Placebo Comparator: Placebo Placebo enzyme cartridges will be used with enteral feedings for 5 days |
Other: Placebo |
Ages Eligible for Study: | 18 Years to 89 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Duke University Hospital
Durham, North Carolina, United States, 27710